indomethacin has been researched along with Morbid Obesity in 1 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Raees, A | 1 |
Bakhamis, A | 1 |
Mohamed-Ali, V | 1 |
Bashah, M | 1 |
Al-Jaber, M | 1 |
Abraham, D | 1 |
Clapp, LH | 1 |
Orie, NN | 1 |
1 other study available for indomethacin and Morbid Obesity
Article | Year |
---|---|
Altered cyclooxygenase-1 and enhanced thromboxane receptor activities underlie attenuated endothelial dilatory capacity of omental arteries in obesity.
Topics: Adipose Tissue; Adult; Apamin; Arteries; Celecoxib; Charybdotoxin; Cyclooxygenase 1; Cyclooxygenase | 2019 |